Literature DB >> 11255522

Warfarin therapy for an octogenarian who has atrial fibrillation.

B F Gage1, S D Fihn, R H White.   

Abstract

In North America, atrial fibrillation is associated with at least 75 000 ischemic strokes each year. Most of these strokes occur in patients older than 75 years of age. The high incidence of stroke in very elderly persons reflects the increasing prevalence of atrial fibrillation that occurs with advanced age, the high incidence of stroke in elderly patients, and the failure of physicians to prescribe antithrombotic therapy in most of these patients. This failure is related to the increased risk for major hemorrhage with advanced age, obfuscating the decision to institute stroke prophylaxis with antithrombotic therapy. This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy. After concluding that the benefits of warfarin outweigh its risks in this patient, we describe how to initiate warfarin therapy cautiously and how to monitor and dose the drug. We then review five recent randomized, controlled trials that document the increased risk for stroke when an international normalized ratio (INR) of less than 2.0 is targeted among patients with atrial fibrillation. Next, we make the case that cardioversion is not needed for this asymptomatic patient with chronic atrial fibrillation. Instead, we choose to leave the patient in atrial fibrillation and to control his ventricular rate with atenolol. Later, when the INR increases to 4.9, we advocate withholding one dose of warfarin and repeating the INR test. Finally, when the patient develops dental pain, we review the analgesic agents that are safe to take with warfarin and explain why warfarin therapy does not have to be interrupted during a subsequent dental extraction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255522     DOI: 10.7326/0003-4819-134-6-200103200-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages.

Authors:  A Cantalapiedra; O Gutierrez; J I Tortosa; M Yañez; M Dueñas; E Fernandez Fontecha; M J Peñarrubia; L J García-Frade
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

3.  Antithrombotic drugs in secondary stroke prevention among a community dwelling older population.

Authors:  F Landi; M Cesari; G Onder; V Zamboni; F Lattanzio; A Russo; C Barillaro; R Bernabei
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

Review 4.  Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Authors:  Eric Pautas; Isabelle Gouin-Thibault; Matthieu Debray; Pascale Gaussem; Virginie Siguret
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 6.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

7.  Frailty Status Affects the Decision for Long-Term Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation.

Authors:  Panteleimon E Papakonstantinou; Natalia I Asimakopoulou; John A Papadakis; Dimitrios Leventis; Michail Panousieris; George Mentzantonakis; Ermis Hoda; Simeon Panagiotakis; Achilleas Gikas
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

8.  Cost of dabigatran for atrial fibrillation.

Authors:  Brian F Gage
Journal:  BMJ       Date:  2011-10-31

9.  Pacing for the suppression of paroxysmal atrial fibrillation in an 87-year-old patient.

Authors:  Paul A Levine; Robin Wachsner; Adel El-Bialy
Journal:  Indian Pacing Electrophysiol J       Date:  2003-04-01

10.  Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.

Authors:  J Pink; M Pirmohamed; D A Hughes
Journal:  Clin Pharmacol Ther       Date:  2013-04-25       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.